

IN THE CLAIMS:

Amend the indicated claims to read as follows:

B 4
4. A composition of claim 3 wherein the antisense sequence is of the formula 5'
-GTGCTCCATTGATGC- 3' (SEQ ID NO: 1) wherein only the terminal sequences are
phosphorothioated.

B 5
9. A method of radiosensitizing tumor tissue by administration of a
radiosensitizing effective amount of at least one antisense oligonucleotide of no more
than 40 bases containing the sequence 5' -GTGCTCCATTGATGC- 3' (SEQ ID NO: 1).

B 6
15. A method of claim 9 wherein the oligonucleotide is of the formula 5' -
GTGCTCCATTGATGC- 3' (SEQ ID NO: 1) and only the end bases [only] are
phosphorothioated.

16. A composition of matter comprising liposomes containing the sequence 5'
-GTGCTCCATTGATGC- 3' (SEQ ID NO: 1) in a pharmaceutically acceptable carrier.

Please add the following claims:

B 7
26. A method of claim 18 wherein the oligonucleotide is administered directly to
the target tissue.

B
27. A method of claim 18 wherein the oligonucleotide is administered into the
arterial supply to the target tissue.

Please cancel claim 11

IN THE ABSTRACT

NB.
At line 4 of the abstract, following the nucleotide sequence, please replace "(seq. #1)"
with "(SEQ ID NO: 1)"

REMARKS

The Present Invention

The present invention is directed to cationic liposomes containing oligonucleotide
sequences and methods of using the inventive compounds to treat radiation-resistant tumors.